Last reviewed 2026-04-22 · How we verify

Oxymetazoline HCL Cream 1.0%

Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing.

Oxymetazoline is an alpha-1 adrenergic agonist that causes vasoconstriction of blood vessels in the skin, reducing redness and flushing. Used for Persistent facial erythema associated with rosacea.

At a glance

Mechanism of action

Oxymetazoline binds to alpha-1 adrenergic receptors on vascular smooth muscle cells, triggering vasoconstriction. This reduces blood flow to the affected area and decreases the appearance of erythema (redness). The cream formulation allows topical application directly to areas of facial redness, providing localized therapeutic effect without systemic absorption.

Approved indications

• Persistent facial erythema associated with rosacea

Common side effects

• Application site erythema
• Application site irritation
• Skin burning or stinging
• Headache

Key clinical trials

• Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea (PHASE3)
• A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea (PHASE3)
• Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Oxymetazoline HCL Cream 1.0% CI brief — competitive landscape report
• Oxymetazoline HCL Cream 1.0% updates RSS · CI watch RSS
• Allergan portfolio CI